tradingkey.logo

REFILE-Lilly requests EMA to reexamine Alzheimer's drug recommendation

ReutersApr 25, 2025 2:28 PM

- Eli Lilly LLY.N has requested Europe's drug regulator to re-examine its opinion on the company's Alzheimer's drug, the agency said on Friday.

Last month, the regulator had rejected the drug, Kisunla, saying that the treatment's ability to slow cognitive decline was not large enough to outweigh the risk of serious brain swelling in patients.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI